Sacituzumab govitecan ‘potential new standard’ for triple-negative breast cancer subset

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic triple-negative breast cancer compared with chemotherapy, according to results from a randomized phase 3 trial.Findings from ASCENT-03, presented at ESMO Congress and co-published in The New England Journal of Medicine, showed patients who received sacituzumab govitecan (Trodelvy,